ONCONETIX INC (ONCO) Stock News
NASDAQ:ONCO - Nasdaq - US68237Q1040 - Common Stock - Currency: USD
ONCO Latest News, Press Relases and Analysis
There are notable gap-ups and gap-downs in today's session.
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Friday.
Stay updated with the stocks that are on the move in today's after-hours session.
Discover the top movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
Cincinnati, OH, May 22, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter from...
Which stocks are moving on Wednesday?
Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Check out the stocks that are attracting the most attention and driving market activity.
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq
Cincinnati, OH, April 30, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (the “Company”) announced that it received a Staff delisting letter...
Why Onconetix (ONCO) Stock Is Exploding Higher
Onconetix shares are trading higher by 85% during Tuesday's session. The company signed a non-binding letter of intent to merge with privately held Ocuvex Therapeutics.
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc.
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort
CINCINNATI, March 24, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) (
Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress
CINCINNATI, March 19, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc., (Nasdaq: ONCO) (“Onconetix” or the “Company”), (formerly Blue Water Biotech, Inc....
Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing
Cincinnati, OH, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (the “Company”) announced that it received a letter from The Nasdaq...